¿´Æ¬Èí¼þ

Saturday 30 November 2024
Salisbury Foundation Trust

FOI_6440

Internal Reference Number: FOI_6440

Date Request Received: 19/01/2022 00:00:00

Date Request Replied To: 04/02/2022 00:00:00

This response was sent via: By Email

Request Summary: Dermatology department use of biologic drugs

Request Category: Companies

 
Question Number 1:
Please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
• Adalimumab - Humira
• Adalimumab Biosimilar
• Apremilast
• Bimekizumab
• Brodalumab
• Certolizumab
• Dimethyl fumarate
• Etanercept - Enbrel
• Etanercept Biosimilar
• Guselkumab
• Infliximab - Remicade
• Infliximab Biosimilar
• Ixekizumab
• Risankizumab
• Secukinumab
• Tildrakizumab
• Ustekinumab
 
Answer To Question 1:
Adalimumab Humira 6
Adalimumab biosimilar 23
Apremilast 2
Bimekizumab 0
Brodalumab 9
Certolizumab 4
Dimethyl Fumarate 0
Etanercept Enbrel 0
Etanercept biosimilar 0
Guselkumab 10
Infliximab Remicade 0
Infliximab biosimilar 0
Ixekizumab 4
Risankizumab 0
Secukinumab 5
Tildrakizumab 3
Ustekinumab 15
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¿´Æ¬Èí¼þ Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

Salisbury ¿´Æ¬Èí¼þ Foundation Trust, Salisbury District Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2024 Salisbury ¿´Æ¬Èí¼þ Foundation Trust
Trust Values